Shandong Weigao Blood Purification Products Co Ltd (810407) News

Christopher Hui: The Hong Kong Stock Exchange has taken into account the needs of different investors when implementing the optimized mechanism for IPO pricing and allocation.

Xu Zhengyu mentioned that the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange will continue to closely review the quality of sponsor work and listing applications, and take appropriate regulatory actions when necessary to uphold Hong Kong's reputation as a leading international fundraising hub.

Zhitong FinanceMay 13 13:51

At a Glance: March's Hottest IPOs - Shangmi Technology Approved! Four New Stocks, Including ZhaoWei Electromechanical and EastControl, Undergoing Enthusiastic Subscription.

Hello, fellow investors! The New Stock Observer is here to provide updates on the popular HK IPOs in March and throughout 2026. Fellow investors, check it out now!

Futu NewsFeb 28 09:55

At a Glance: February's Hottest IPOs - Dongpeng Beverage and Guoen Technology Are Set to Go Public! Five New Stocks Including Montage Technology and Aixing Yuanzhi Are Under Active Subscription.

Hello, fellow investors! The NiuNiu New Shares team is pleased to present the popular IPOs in HK for February and 2026. Fellow investors, feel free to check them out~

Futu NewsJan 30 14:17

At a Glance: January's Hottest IPOs: First of the New Year! Biren Technology listed on the Hong Kong Stock Exchange on January 2nd, with 10 new stocks including Zhipu, MINIMAX, and TianShuZhiXin in active subscription.

Hello, fellow investors! The Futu IPO Assistant is here to provide you with the most popular IPOs in HK for January and 2026. Fellow investors, come and check them out!

Futu NewsDec 31, 2025 15:57

KPMG: Hong Kong regains top spot in global IPO fundraising this year, with an estimated HKD 272.1 billion raised.

KPMG's latest report, 'Review of the 2025 IPO Market in Mainland China and Hong Kong and Outlook for 2026,' highlights that Hong Kong regained its position as the top global IPO market in 2025, marking its return to the leading spot since 2019. The number of A+H share listings this year reached a new high, accounting for over half of the total funds raised throughout the year, propelling Hong Kong’s IPO market performance to rank first globally. As of December 7, the number of listing applications in Hong Kong hit a record high, with over 300 filings in total, including 92 A+H share listing applications. The report notes that, this year, the global IPO market collectively raised USD 158.4 billion through 1,227 listings.

AASTOCKSDec 10, 2025 17:41

The market size exceeds 50 billion! Another hemodialysis giant plans to go public

合壹滙科技Jun 28, 2022 15:53

IPO | Weigao Blood Purification, a leading company in the Chinese blood purification market, submitted the list to the Hong Kong Stock Exchange

On June 28, Capital Bank learned that Shandong Weigao Blood Purification Products Co., Ltd. submitted a listing to the main board of the Hong Kong Stock Exchange, with Citigroup, Huatai International and Huaxing Capital as co-sponsors. According to the prospectus, the company is a leading enterprise in the Chinese blood purification market. It is in a leading position in all major tracks in the field of blood purification, leading domestic substitution. In 2021, the company's dialyzer sales accounted for 32.4%, ranking first in the country, and blood pipeline sales accounted for 32.6%, ranking first in the country and far exceeding second place. The sales of hemodialysis machines sold exclusively domestically accounted for the total sales of domestic hemodialysis machines

ChinaIPO NewsJun 28, 2022 14:50

Vigor Blood Purification Submits Listing Application

Veigor's blood purification submits a listing application to the Stock Exchange with the joint sponsors Citi, Huatai International and Huaxing Capital. Earlier, external news said that Weigao's blood purification target raised about $500 million. The company mainly provides comprehensive blood purification products, including dialyzer, dialysis machine, blood line and other hemodialysis products, peritoneal dialysis products such as peritoneal dialysis. Currently, there are 219 self-developed hemodialysis products. According to market research institutes, the company's dialyzer sales market share in 2021 was 32.4% and blood pipeline sales market share of 32.6%, ranked first in the Mainland market. Initial IPO

即市頭條Jun 28, 2022 10:04

New stock news | Vega Blood purification delivery form HKEx is the leading company in China's blood purification market.

Shandong Weigao Blood purification products Co., Ltd. submitted an application for listing to the Hong Kong Stock Exchange, with Citigroup, Huatai International and China Renaissance Capital Investment as its co-sponsors, Zhitong Financial APP learned. According to the prospectus, China's blood purification market has a huge base, rapid growth and huge growth potential. As a leading enterprise, Weigao Blood purification is in a leading position in all major tracks in the field of blood purification, leading domestic substitutes. The number of patients with end-stage renal disease (ESRD) in China is huge, reaching 3.59 million in 2021. According to Frost Sullivan's forecast, the number of ESRD patients in China in 2026

Zhitong FinanceJun 27, 2022 22:43

The technical difficulties have not been solved, and profit space is limited. Where is the path for domestic hemodialysis companies?

Only by cracking the “stuck neck” technology can domestic brands make a comeback in the collection

財經大健康Jun 21, 2022 17:41

Lu Zhishen｜The “Weigao Phenomenon” in the capital market

魯網Jun 17, 2022 17:23

Weigao and Huawei sign comprehensive cooperation agreement

On June 15, the signing ceremony for the comprehensive cooperation agreement & digital planning consulting project between Weigao Group and Huawei was held in Shenzhen. Che Haiping, senior vice president of Huawei and chief strategy officer for digital transformation, and Long Jing, president of Weigao Group, attended the ceremony and signed.

威高血液淨化Jun 17, 2022 09:04

Raising 3.4 billion dollars, the “King of Hemodialysis in China” will go public

藍點新科技Jun 16, 2022 06:29

Securities Regulatory Commission: Shandong Weigao Blood Purification Products Co., Ltd.'s overseas IPO application has received materials

The Zhitong Finance App learned that on June 10, the China Securities Regulatory Commission announced the progress of the “approval of overseas initial public offerings of shares (including common shares, preferred shares, etc., and derivative forms of stocks)” of Shandong Weigao Blood Purification Products Co., Ltd., which has now reached the stage of receiving materials.

Zhitong FinanceJun 11, 2022 16:44

Weigao Blood Purification plans to go public in a Hong Kong H-share IPO. An application has been submitted to the China Securities Regulatory Commission

On June 10, 2022, the International Department of the China Securities Regulatory Commission disclosed the “Approval for the Initial Public Offering of Shares Abroad by the Joint Stock Company (including common shares, preferred shares, and other types of stocks and stock derivatives)” submitted by Shandong Weigao Blood Purification Products Co., Ltd. (hereinafter referred to as “Weigao Blood Purification”).

瑞恩資本Jun 11, 2022 14:01